Furthermore, whilst oncogenic process associated with IDH-based metabolic heterogeneity/homogeneity may be sufficient to promote GBM primary tumour progression, there remains a knowledge gap as to whether such associations are necessary for re-growth of GBM from post-treatment residual disease cells from the GBM invasive margin and brain parenchyma beyond. The gene discussed is IDH1; the disease is neoplasm.